Xavier Millán

Xavier Millán

Auto-generated profile, based on publicly available information

Xavier Millán

Department of Cardiology, Hospital Universitari de la Santa Creu i Sant Pau, IB Sant Pau, Barcelona, Spain (X.M., D.A.).

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
XMXavier Millán
Xavier Millán
SSSabah Skaf
Sabah Skaf
LJLawrence Joseph
Lawrence Joseph
CRCarlos Ruiz
Carlos Ruiz
EGEulogio García
Eulogio García
EJE. Marc Jolicœur
E. Marc Jolicœur

23 December 2025 in Circulation
Verified
Journal Article
Closed access
JRJosep Rodés-Cabau
Josep Rodés-Cabau
LNLuis Nombela
Luis Nombela
ICIgnacio Cruz-Gonzalez
Ignacio Cruz-Gonzalez
BHBenjamin Hibbert
Benjamin Hibbert
XFXavier Freixa
Xavier Freixa
ESErwan Salaun
Erwan Salaun
BACKGROUND: The optimal antithrombotic treatment after transcatheter left atrial appendage closure (LAAC) remains to be determined. The objective of this trial was to compare anticoagulation and antiplatelet therapy for preventing device-related thrombosis (DRT) after LAAC. METHODS: This was a prospective multicenter international randomized trial comparing 2 different antithrombotic strategies for preventing DRT after LAAC in patients with nonvalvular atrial fibrillation. Patients were randomized (1:1) to receive direct oral anticoagulants (DOACs) or dual antiplatelet therapy (DAPT; aspirin+clopidogrel) for 60 days. Patients underwent transesophageal echocardiography at 60 days, and the images were analyzed in a central echocardiography laboratory by experienced echocardiographers blinded to the allocated treatment. The primary outcome was DRT as determined by transesophageal echocardiography 60 days after LAAC in patients receiving the allocated treatment at the time of transesophageal echocardiography (per-protocol analysis). The safety outcome included all-cause mortality, stroke, bleeding, or site-reported DRT within 60 days after LAAC in all randomized patients (intention-to-treat analysis). RESULTS: A total of 510 patients (mean age 77±9 years, 35% women) were included between October 2018 and May 2025, and 253 and 257 patients were randomized to the DOAC and DAPT groups, respectively. Of these, 399 patients underwent transesophageal echocardiography and were receiving the allocated treatment at 60 days after LAAC. The primary outcome occurred in 3 patients (1.5%) in the DOAC group compared with 8 patients (4.1%) in the DAPT group (difference, −2.7% [95% CI, −6.0% to 0.6%]; P =0.110). The safety outcome occurred in 52 patients (22.5%) in the DOAC group compared with 82 patients (34.9%) in the DAPT group (difference, −12.4% [95% CI, −20.6% to −4.2%]; P =0.003), and differences were mainly driven by a lower rate of bleeding events in the DOAC group (44 patients [17.4%] versus 64 patients [24.9%]; difference, −7.5% [95% CI, −14.6% to −0.4%]; P =0.038). CONCLUSIONS: The use of DOACs after LAAC failed to reduce DRT compared with DAPT, but it was associated with an improved safety profile. The results of this study should be interpreted with caution because of statistical power issues related to the narrower-than-expected between-group differences and will need confirmation in future larger studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03568890.

17 April 2015 in Journal of Interventional Cardiology
Verified
Journal Article
Closed access
PDF file
LALorenzo Azzalini
Lorenzo Azzalini
XMXavier Millán
Xavier Millán
HLHung Q. Ly
Hung Q. Ly
PLPhilippe L. L'Allier
Philippe L. L'Allier
EJE. Marc Jolicoeur
E. Marc Jolicoeur

18 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EJElena Jimenez-Xarrie
Elena Jimenez-Xarrie
LALluís Asmarats
Lluís Asmarats
MRMarta Roqué-Figuls
Marta Roqué-Figuls
XMXavier Millán
Xavier Millán
CLChi Hion Pedro Li
Chi Hion Pedro Li
DADabit Arzamendi
Dabit Arzamendi
Transcatheter aortic valve replacement (TAVR) is currently the treatment of choice for patients aged ≥75 years with severe aortic stenosis. Preoperative anemia is present in a large proportion of patients and may increase the risk of post-procedural complications. The purpose of this prognostic systematic review was to analyze the impact of baseline anemia on short- and mid-term outcomes following TAVR. A computerized search was performed on PubMed and Web of Science databases for studies published between January 2013 and December 2022. Primary outcomes were 30-day need for transfusion, acute renal failure, 30-day and mid-term mortality, and readmission during the first year post-TAVR. Data were analyzed via random effects model using inverse variance method with 95% confidence intervals. Eleven observational studies met our eligibility criteria and included a total of 12,588 patients. The prevalence of baseline anemia ranged between 39% and 72%, with no relevant sex differences. Patients with preprocedural anemia received more blood transfusions [OR: 2.95 (2.13–4.09)]), and exhibited increased rates of acute kidney injury [OR:1.74 (1.45–2.10)], short-term mortality [OR: 1.47 (1.07–2.01], and mid-term [OR: 1.89 (1.58–2.25)] mortality following TAVR compared with those without anemia. Baseline anemia determined an increased risk for blood transfusion, acute kidney injury, and short/mid-term mortality among TAVR recipients.

1 August 2020 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
IPIsaac Pascual
Isaac Pascual
DADabit Arzamendi
Dabit Arzamendi
FCFernando Carrasco-Chinchilla
Fernando Carrasco-Chinchilla
FFFelipe Fernández-Vázquez
Felipe Fernández-Vázquez
XFXavier Freixa
Xavier Freixa
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro

1 April 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
APAndreu Porta-Sánchez
Andreu Porta-Sánchez
José BarrabésJosé Barrabés
José Barrabés
JFJaume Figueras
Jaume Figueras
XMXavier Millan
Xavier Millan
ASAntonia Sambola
Antonia Sambola
DGDavid Garcia-Dorado
David Garcia-Dorado